Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide’s clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders
Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the
Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, reports financial
- Second quarter 2019 revenues increased 45% and commercial samples increased 26% over the second quarter of 2018 - Revenues for the first six-month of 2019 increased 36% and commercial samples increased 18% over the first six months of 2018 - Conference call begins at 4:30 p.m.
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
- Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition- Launch of "AND" campaign supports growth in test volume both sequentially and year-over-year- New provider agreements with both Scripps Health Plan and MediNcrease expand patient access to Biocept's proprietary liquid biopsy test platform- Secures $2.2 million investment from Ally Bridge LB Healthcare Master Fund- Evaluating strategic opportunities in China with Ally Bridge's Chinese affiliate- Company to host conference call at 4:30 p.m. Eastern time today
Significantly Increases Sample Volume and Number of Biomarker Assays per Sample Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to six new employees.
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees.
